About this trial
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.
In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically proven diagnosis of thymic malignancies
18 years of age or older
Ability to understand and the willingness to sign a written informed consent document
Disqualifiers
None
Trial population
Participants with thymic malignancies are with the standard treatment and/or are enrolled in the clinical trials.
Trial design
Case-only
Prospective
Treatments tested in this trial
Chemotherapy
Drugdifferent treatments based on the molecular analysis
Treatment groups
Trial outcomes
Primary outcomes
Objective response rate (ORR)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Disease control rate (DCR)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Progression-free survival (PFS)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Secondary outcomes
Overall survival (OS)
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Sponsors and contacts
Click on the lead sponsor to view all of their trials.